MetaCap

Precipio Inc. (PRPO)

NASDAQ: PRPOIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD

17.35-1.14 (-6.17%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PRPO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$31.11M
EPS (TTM)
-$0.59
52-week range
17.30 – 33.63
Day range
17.30 – 19.11
Volume / Avg
35.65K / 79.50K
Beta
—

52-week range

$17.30$33.63

PRPO stock today

On Nov 20, PRPO ended the session at $17.35, shedding $1.14 (6.17%), versus the S&P 500's 3.70% decline. Trading was light, with 35.65K shares changing hands, about 45% of the average daily volume. Shares are 48.4% below their 52-week high of $33.63, set on May 6, 2026 and 0.3% above the 52-week low of $17.30, near the bottom of the past year's range.

PRPO is down 24.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 29.2%. Precipio has posted a net loss over the last twelve months (EPS of -$0.59), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Precipio

Company profile

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages.

Industry
Biotechnology: Laboratory Analytical Instruments
CEO
Mr. Ilan Danieli
Headquarters
New Haven, CT
Employees
61

Financial highlights

Full financials

In fiscal 2025, Precipio generated $24.0 million in revenue, up 29.8% from fiscal 2024, its 8th consecutive year of revenue growth. Precipio reported a net loss of $363,000, compared with a loss of $4.3 million a year earlier. Gross margin was 44.5% (up from 40.8%) and operating margin -5.0%.

Precipio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$24.05M$18.53M$15.20M$9.41M$8.85M
Growth+29.77%+21.95%+61.46%+6.36%+45.26%
Net income$-363.00K$-4.29M$-5.85M$-12.18M$-8.52M
EPS (diluted)$-0.23$-2.93$-4.51$-10.73$-0.40

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.05 vs —

PRPO news

All PRPO news

Precipio peers

Industrials sector
PRPO peer companies
CompanyPrice% ChgMarket capCompare
EYPTEyePoint Inc.0.2342-11.36%$26.65Mvs PRPO
RPIDRapid Micro Biosystems Inc. Class A0.735-0.04%$37.37Mvs PRPO
HBIOHarvard Bioscience Inc.8.66-0.23%$39.60Mvs PRPO
CIRCCircle8 Group Inc.0.1361-12.25%$15.99Mvs PRPO
BNGOBionano Genomics Inc.0.8222-7.11%$11.50Mvs PRPO
ASTCAstrotech Corporation (DE)3.50-0.85%$7.45Mvs PRPO
SEERSeer Inc. Class A1.36-1.81%$75.91Mvs PRPO
QTRXQuanterix Corporation1.96-3.45%$93.06Mvs PRPO

Indexes, lists and sector

Precipio stock FAQ

What is Precipio's stock price today?

PRPO last traded at $17.35 as of Nov 20, 4:00 PM EST, down 6.17% on the day. Prices are delayed at least 15 minutes.

Does Precipio pay a dividend?

No. Precipio does not currently pay a regular cash dividend.

Who is Precipio's CEO?

Mr. Ilan Danieli is the chief executive officer of Precipio Inc., which has about 61 employees.

Has PRPO ever split its stock?

Yes. The most recent PRPO stock split was a 1-for-20 split on Sep 22, 2023, one of 2 splits on record.

What is the PRPO 52-week high?

The 52-week high for PRPO is $33.63 and the 52-week low is $17.30. The stock is currently 48.4% below its high.

Compare PRPO